During the past few years, jaundice has been reported rather frequently as a complication of several drugs of recent innovation, particularly those of the tranquilizer group. The clinical picture has been rather characteristic. The patient, when placed on therapy with the agent, in about 14 days develops fever, nausea, abdominal pain, muscle ache, and jaundice, in association with dark urine and light stools. The jaundice is usually gone within a few weeks but may continue for several months. Complete recovery is observed in most cases, but fatal agranulocytosis may occur. No particular treatment is indicated.
The laboratory data are those of an intrahepatic type of obstructive jaundice. The bilirubin level, particularly the direct fraction, is elevated, as are the alkaline phosphatase and cholesterol levels. There are no evidences of hepatocellular damage; cephalin flocculation is negative; and thymol turbidity, total serum protein level, and prothrombin time are all normal. The urine